Of the tracked stories, 3 of 3 also mention Bezos Earth Fund, the most common co-covered peer. The clearest coverage concentration is sustainability: 2 of 3 stories, with the rest divided among 1 other category. Re:wild appears in 3 tracked Cross-Sector stories from August 4, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Re:wild
Of the tracked stories, 3 of 3 also mention Bezos Earth Fund, the most common co-covered peer. The clearest coverage concentration is sustainability: 2 of 3 stories, with the rest divided among 1 other category. Re:wild appears in 3 tracked Cross-Sector stories from August 4, 2026. The tracked stories average 2 original sources each.
Stories tracked
3
Sources per story
2
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Re:wild. Shared-story counts are live from our verified record — not editorial picks.
The Phoenix Species Project, backed by $200 million from Re:wild and the Bezos Earth Fund, aims to revive 100 critically endangered species whose habitats are threatened by climate change. This landmark fund, the largest ever dedicated to species recovery, signals a growing integration of biodiversity protection into climate resilience strategies. By targeting iconic and indicator species, it seeks to leverage philanthropy for measurable ecosystem stability.
The Phoenix Species Project directly ties species survival to climate resilience, marking a paradigm shift in how private capital addresses climate-driven biodiversity loss. The $200 million fund aims to reverse declines for 100 species, setting a new benchmark for climate-adaptive conservation.
The DiCaprio/Bezos-backed $200M Phoenix Species Project promises to accelerate demand for genetic rescue, biobanking, and conservation biotech tools. For pharma and biotech players, it signals new funding channels and biodiversity prospecting potential.
